APLT Stock Summary and Trading Ideas (Applied Therapeutics | NASDAQ:APLT)

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Applied Therapeutics trades on the NASDAQ stock market under the symbol APLT.

As of December 24, 2025, APLT stock price was flat at $0.12 with 6,452,379 million shares trading.

APLT has a beta of 2.54, meaning it tends to be more sensitive to market movements. APLT has a correlation of 0.04 to the broad based SPY ETF.

APLT has a market cap of $16.65 million. This is considered a Sub-Micro Cap stock.

Last quarter Applied Therapeutics reported $1 million in Revenue and -$.13 earnings per share. This beat revenue expectation by $750,000 and exceeded earnings estimates by $.01.

In the last 3 years, APLT traded as high as $10.62 and as low as $.10.

The top ETF exchange traded funds that APLT belongs to (by Net Assets): VTI, VXF, VHT, MSSM.

APLT has underperformed the market in the last year with a price return of -86.7% while the SPY ETF gained +17.3%. APLT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -74.6% and -53.9%, respectively, while the SPY returned +4.4% and +1.4%, respectively.

APLT support price is $.11 and resistance is $.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APLT shares will trade within this expected range on the day.